These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

439 related articles for article (PubMed ID: 26850655)

  • 1. The effect of increasing the dose of hydroxychloroquine (HCQ) in patients with refractory cutaneous lupus erythematosus (CLE): An open-label prospective pilot study.
    Chasset F; Arnaud L; Costedoat-Chalumeau N; Zahr N; Bessis D; Francès C
    J Am Acad Dermatol; 2016 Apr; 74(4):693-9.e3. PubMed ID: 26850655
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study.
    Francès C; Cosnes A; Duhaut P; Zahr N; Soutou B; Ingen-Housz-Oro S; Bessis D; Chevrant-Breton J; Cordel N; Lipsker D; Costedoat-Chalumeau N
    Arch Dermatol; 2012 Apr; 148(4):479-84. PubMed ID: 22508872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Steady-state pharmacokinetics of hydroxychloroquine in patients with cutaneous lupus erythematosus.
    Al-Rawi H; Meggitt SJ; Williams FM; Wahie S
    Lupus; 2018 Apr; 27(5):847-852. PubMed ID: 28862574
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Hydroxychloroquine in Patients With Cutaneous Lupus Erythematosus: A Multicenter, Double-Blind, Randomized, Parallel-Group Trial.
    Yokogawa N; Eto H; Tanikawa A; Ikeda T; Yamamoto K; Takahashi T; Mizukami H; Sato T; Yokota N; Furukawa F
    Arthritis Rheumatol; 2017 Apr; 69(4):791-799. PubMed ID: 27992698
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: A retrospective cohort study.
    Mittal L; Zhang L; Feng R; Werth VP
    J Am Acad Dermatol; 2018 Jan; 78(1):100-106.e1. PubMed ID: 28989103
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent findings about antimalarials in cutaneous lupus erythematosus: What dermatologists should know.
    Teboul A; Arnaud L; Chasset F
    J Dermatol; 2024 Jul; 51(7):895-903. PubMed ID: 38482997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxychloroquine administration for Japanese lupus erythematosus in Wakayama: a pilot study.
    Ikeda T; Kanazawa N; Furukawa F
    J Dermatol; 2012 Jun; 39(6):531-5. PubMed ID: 22168306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis.
    Chasset F; Bouaziz JD; Costedoat-Chalumeau N; Francès C; Arnaud L
    Br J Dermatol; 2017 Jul; 177(1):188-196. PubMed ID: 28112801
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS Study).
    Costedoat-Chalumeau N; Galicier L; Aumaître O; Francès C; Le Guern V; Lioté F; Smail A; Limal N; Perard L; Desmurs-Clavel H; Boutin du LT; Asli B; Kahn JE; Pourrat J; Sailler L; Ackermann F; Papo T; Sacré K; Fain O; Stirnemann J; Cacoub P; Jallouli M; Leroux G; Cohen-Bittan J; Tanguy ML; Hulot JS; Lechat P; Musset L; Amoura Z; Piette JC;
    Ann Rheum Dis; 2013 Nov; 72(11):1786-92. PubMed ID: 23144449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cumulative dose of hydroxychloroquine is associated with a decrease of resting heart rate in patients with systemic lupus erythematosus: a pilot study.
    Cairoli E; Danese N; Teliz M; Bruzzone MJ; Ferreira J; Rebella M; Cayota A
    Lupus; 2015 Oct; 24(11):1204-9. PubMed ID: 25852050
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Population Pharmacokinetics of Hydroxychloroquine in Japanese Patients With Cutaneous or Systemic Lupus Erythematosus.
    Morita S; Takahashi T; Yoshida Y; Yokota N
    Ther Drug Monit; 2016 Apr; 38(2):259-67. PubMed ID: 26587870
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature.
    Chasset F; Francès C; Barete S; Amoura Z; Arnaud L
    J Am Acad Dermatol; 2015 Apr; 72(4):634-9. PubMed ID: 25648824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changing antimalarial agents after inefficacy or intolerance in patients with cutaneous lupus erythematosus: A multicenter observational study.
    Chasset F; Arnaud L; Jachiet M; Monfort JB; Bouaziz JD; Cordoliani F; Bagot M; Barbaud A; Francès C
    J Am Acad Dermatol; 2018 Jan; 78(1):107-114.e1. PubMed ID: 29061479
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Varied responses to and efficacies of hydroxychloroquine treatment according to cutaneous lupus erythematosus subtypes in Japanese patients.
    Ototake Y; Yamaguchi Y; Kanaoka M; Akita A; Ikeda N; Aihara M
    J Dermatol; 2019 Apr; 46(4):285-289. PubMed ID: 30719729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hydroxychloroquine Blood Levels in Systemic Lupus Erythematosus: Clarifying Dosing Controversies and Improving Adherence.
    Durcan L; Clarke WA; Magder LS; Petri M
    J Rheumatol; 2015 Nov; 42(11):2092-7. PubMed ID: 26428205
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of
    Gardet A; Pellerin A; McCarl CA; Diwanji R; Wang W; Donaldson D; Franchimont N; Werth VP; Rabah D
    Front Immunol; 2019; 10():275. PubMed ID: 30846987
    [No Abstract]   [Full Text] [Related]  

  • 17. Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis.
    Chang AY; Piette EW; Foering KP; Tenhave TR; Okawa J; Werth VP
    Arch Dermatol; 2011 Nov; 147(11):1261-7. PubMed ID: 21768444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenalidomide treatment of cutaneous lupus erythematosus: the Mayo Clinic experience.
    Kindle SA; Wetter DA; Davis MD; Pittelkow MR; Sciallis GF
    Int J Dermatol; 2016 Aug; 55(8):e431-9. PubMed ID: 26873674
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxychloroquine does not impair antibody response to 13-valent pneumococcal conjugate vaccine in patients with cutaneous lupus erythematosus-A pilot study.
    Pelka K; Matyja-Bednarczyk A; Wojas-Pelc A; Pastuszczak M
    Dermatol Ther; 2021 Jul; 34(4):e15013. PubMed ID: 34056799
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity.
    Ugarte A; Porta S; Ríos R; Martinez-Zapico A; Ortego-Centeno N; Agesta N; Ruiz-Irastorza G
    Lupus; 2018 Sep; 27(10):1718-1722. PubMed ID: 29635998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.